Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 By: ChromaDex Corporation via Business Wire May 23, 2024 at 08:34 AM EDT ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with the ChromaDex management team, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/. For additional Investor Relation information on ChromaDex, visit www.chromadex.com. About ChromaDex: ChromaDex Corp. (NASDAQ: CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. NIAGEN NR is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024). View source version on businesswire.com: https://www.businesswire.com/news/home/20240523712197/en/ ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 Contacts ChromaDex Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-388-6706 ext. 689 kendall.knysch@chromadex.com ChromaDex Investor Relations Contact: Ben Shamsian Lytham Partners 646-829-9701 shamsian@lythampartners.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 By: ChromaDex Corporation via Business Wire May 23, 2024 at 08:34 AM EDT ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with the ChromaDex management team, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/. For additional Investor Relation information on ChromaDex, visit www.chromadex.com. About ChromaDex: ChromaDex Corp. (NASDAQ: CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. NIAGEN NR is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024). View source version on businesswire.com: https://www.businesswire.com/news/home/20240523712197/en/ ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 Contacts ChromaDex Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-388-6706 ext. 689 kendall.knysch@chromadex.com ChromaDex Investor Relations Contact: Ben Shamsian Lytham Partners 646-829-9701 shamsian@lythampartners.com
ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with the ChromaDex management team, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/. For additional Investor Relation information on ChromaDex, visit www.chromadex.com. About ChromaDex: ChromaDex Corp. (NASDAQ: CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. NIAGEN NR is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024). View source version on businesswire.com: https://www.businesswire.com/news/home/20240523712197/en/
ChromaDex Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-388-6706 ext. 689 kendall.knysch@chromadex.com ChromaDex Investor Relations Contact: Ben Shamsian Lytham Partners 646-829-9701 shamsian@lythampartners.com